Nanobiotix

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

Placement of 1,596,527 new shares, representing 10% of Nanobiotix’ pre-deal outstanding share capital
Issue price of €15.75 per share represented a limited 1.4% discount versus the year-to-date average closing price
Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner in this transaction